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ABSTRACT
The aim of this study was to establish an evidence-based guideline for the antibiotic treatment 
of Corynebacterium striatum infections. Several electronic databases were systematically 
searched for clinical trials, observational studies or individual cases on patients of any age and 
gender with systemic inflammatory response syndrome, harboring C. striatum isolated from 
body fluids or tissues in which it is not normally present. C. striatum had to be identified as 
the only causative agent of the invasive infection, and its isolation from blood, body fluids or 
tissues had to be confirmed by one of the more advanced diagnostic methods (biochemical 
methods, mass spectrometry and/or gene sequencing). This systematic review included 
42 studies that analyzed 85 individual cases with various invasive infections caused by 
C. striatum. More than one isolate of C. striatum exhibited 100% susceptibility to vancomycin, 
linezolid, teicoplanin, piperacillin-tazobactam, amoxicillin-clavulanate and cefuroxime. 
On the other hand, some strains of this bacterium showed a high degree of resistance to 
fluoroquinolones, to the majority majority of β-lactams, aminoglycosides, macrolides, 
lincosamides and cotrimoxazole. Despite the antibiotic treatment, fatal outcomes were reported 
in almost 20% of the patients included in this study. Gene sequencing methods should be the 
gold standard for the identification of C. striatum, while MALDI-TOF and the Vitek system 
can be used as alternative methods. Vancomycin should be used as the antibiotic of choice for 
the treatment of C. striatum infections, in monotherapy or in combination with piperacillin-
tazobactam. Alternatively, linezolid, teicoplanin or daptomycin may be used in severe infections, 
while amoxicillin-clavulanate may be used to treat mild infections caused by C. striatum.
KEYWORDS: Corynebacterium striatum. Invasive infection. Antibiotic treatment. 
Systematic review.
INTRODUCTION
Corynebacterium striatum is a non-diphtheric gram-positive, aerobic and 
facultative anaerobic, non-sporulating and immobile bacillus1,2. Although this 
bacterium is a normal resident of skin and mucous membranes in humans, a 
large number of different invasive infections caused by this species have been 
reported in the last two decades3. C. striatum causes serious infections primarily 
in immunocompromised patients, such as those in the terminal stage of cancer 
and presenting with other critical conditions4. In addition, invasive diagnostic 
and therapeutic procedures, long-term use of broad-spectrum antibiotics and 
prolonged hospitalization were also identified as relevant risk factors for C. striatum 
infections5,6. However, there is a growing evidence that C. striatum can cause serious 
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infections in immunocompetent hosts, as well6. In addition, 
cases of patient-to-patient spreading of C. striatum with 
serious nosocomial outbreaks are described in intensive care 
units. Therefore, in many countries, nowadays, C. striatum 
is considered as an emerging pathogen7,8.
To the best of our knowledge, no evidence-based 
guidelines have been proposed to date to support an 
adequate antibiotic therapy for C. striatum infections. Only 
one review summarized the combination of amoxicillin 
and rifampin in the treatment of bone and joint infections9. 
Current evidence suggests certain antibiotics for the 
treatment of these infections based on in vitro susceptibility 
testing10,11. The resistance of C. striatum to a large number of 
antimicrobial agents used to treat gram-positive infections, 
such as penicillin, ceftriaxone, meropenem, clindamycin 
and tetracycline, has been deeply studied10. Since the causal 
role of C. striatum in the development of different types of 
invasive infections is undeniable, the doses and duration of 
antibiotic therapy can vary significantly. Given all of the 
above, there is a growing need to establish evidence-based 
guidelines for the antibiotic treatment of C.  striatum 
infections.
Therefore, based on the available literature evidence on 
previously successful antibiotic treatment for C. striatum 
infections, our attempt was to elaborate a guide that could 
help physicians to address this rare, although potentially 
serious problem in clinical practice.
MATERIALS AND METHODS
The research protocol was initially registered at 
PROSPERO database of systematic review articles and 
meta-analyzes (registration Nº CRD42020185512).
Different types of articles (case reports, case series, 
clinical trials, observational studies) were considered as 
data sources for this research. Patients of any gender or 
age were included in the systematic examination if they 
were infected with C.  striatum. The bacterium had to 
be identified as the only causative agent of the invasive 
infection, and its isolation from blood, body fluids or tissues 
had to be confirmed by one of the more advanced diagnostic 
methods (Vitek 2, API or BD Phoenix biochemical systems, 
MALDI-TOF mass spectrometry and/or by 16s RNA 
sequencing).
Articles were excluded if the data of patients were 
incomplete, if C.  striatum was not the only isolated 
microorganism (mixed infections), in case the full text of 
the article was not found or if the article was found to be 
irrelevant (C.  striatum was only mentioned in the text). 
There were no additional restrictions on the language or 
date of publication.
The following electronic databases were searched: 
MEDLINE (PubMed), EBSCO (Discovery Service), 
SCOPUS, SCIndex (Serbian Citation Index), Cochrane 
database of published clinical trials – Central (Wiley Online 
Library), and ClinicalTrials.gov (U.S. National Library of 
Medicine). The database search included all studies with 
human participants published until November 15, 2020.
All authors, except for the senior investigator (SJ), 
independently searched for the mentioned databases, 
according to their own search strategy. MM’s search strategy 
provided the highest number of results in the MEDLINE 
database:
(“corynebacterium striatum”[Supplementary 
Concept] OR “corynebacterium striatum”[All Fields] 
OR “corynebacterium striatum”[All Fields]) AND 
(((“invasibility”[All Fields] OR “invasible”[All Fields] 
OR “invasion”[All Fields] OR “invasions”[All Fields] OR 
“invasive”[All Fields] OR “invasively”[All Fields] OR 
“invasiveness”[All Fields] OR “invasives”[All Fields] OR 
“invasivity”[All Fields]) AND (“infect”[All Fields] OR 
“infectability”[All Fields] OR “infectable”[All Fields] 
OR “infectant”[All Fields] OR “infectants”[All Fields] 
OR “infected”[All Fields] OR “infecteds”[All Fields] OR 
“infectibility”[All Fields] OR “infectible”[All Fields] OR 
“infecting”[All Fields] OR “infection s”[All Fields] OR 
“infections”[MeSH Terms] OR “infections”[All Fields] 
OR “infection”[All Fields] OR “infective”[All Fields] 
OR “infectiveness”[All Fields] OR “infectives”[All 
Fields] OR “infectivities”[All Fields] OR “infects”[All 
Fields] OR “pathogenicity”[MeSH Subheading] OR 
“pathogenicity”[All Fields] OR “infectivity”[All 
Fields])) OR (“endocarditis”[MeSH Terms] OR 
“endocarditis”[All Fields] OR “endocarditides”[All 
Fields])  OR (“osteomyeli t ies”[All  Fields]  OR 
“osteomyelitis”[MeSH Terms] OR “osteomyelitis”[All 
Fields] OR “osteomyelit ides”[All  Fields])  OR 
(“arthritis”[MeSH Terms] OR “arthritis”[All Fields] OR 
“arthritides”[All Fields] OR “polyarthritides”[All Fields]) 
OR ((“prosthetic”[All Fields] OR “prosthetically”[All 
Fields] OR “prosthetics”[All Fields]) AND (“joint s”[All 
Fields] OR “joints”[MeSH Terms] OR “joints”[All Fields] 
OR “joint”[All Fields]) AND (“infect”[All Fields] OR 
“infectability”[All Fields] OR “infectable”[All Fields] 
OR “infectant”[All Fields] OR “infectants”[All Fields] 
OR “infected”[All Fields] OR “infecteds”[All Fields] OR 
“infectibility”[All Fields] OR “infectible”[All Fields] OR 
“infecting”[All Fields] OR “infection s”[All Fields] OR 
“infections”[MeSH Terms] OR “infections”[All Fields] 
OR “infection”[All Fields] OR “infective”[All Fields] 
OR “infectiveness”[All Fields] OR “infectives”[All 
Fields] OR “infectivities”[All Fields] OR “infects”[All 
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Fields] OR “pathogenicity”[MeSH Subheading] OR 
“pathogenicity”[All Fields] OR “infectivity”[All Fields])) 
OR ((“joint s”[All Fields] OR “joints”[MeSH Terms] 
OR “joints”[All Fields] OR “joint”[All Fields]) AND 
(“infect”[All Fields] OR “infectability”[All Fields] OR 
“infectable”[All Fields] OR “infectant”[All Fields] OR 
“infectants”[All Fields] OR “infected”[All Fields] OR 
“infecteds”[All Fields] OR “infectibility”[All Fields] OR 
“infectible”[All Fields] OR “infecting”[All Fields] OR 
“infection s”[All Fields] OR “infections”[MeSH Terms] 
OR “infections”[All Fields] OR “infection”[All Fields] 
OR “infective”[All Fields] OR “infectiveness”[All Fields] 
OR “infectives”[All Fields] OR “infectivities”[All Fields] 
OR “infects”[All Fields] OR “pathogenicity”[MeSH 
Subheading] OR “pathogenicity”[All Fields] OR 
“infectivity”[All Fields])) OR (“synovitis”[MeSH Terms] 
OR “synovitis”[All Fields] OR “synovitides”[All Fields]) 
OR (“peritoneally”[All Fields] OR “peritoneum”[MeSH 
Terms] OR “peritoneum”[All Fields] OR “peritoneal”[All 
Fields] OR “peritonism”[All Fields] OR “peritonitis”[MeSH 
Terms] OR “peritonitis”[All Fields]) OR ((“peritoneal 
dialysis, continuous ambulatory”[MeSH Terms] OR 
(“peritoneal”[All Fields] AND “dialysis”[All Fields] AND 
“continuous”[All Fields] AND “ambulatory”[All Fields]) 
OR “continuous ambulatory peritoneal dialysis”[All Fields] 
OR “capd”[All Fields]) AND (“peritoneally”[All Fields] 
OR “peritoneum”[MeSH Terms] OR “peritoneum”[All 
Fields] OR “peritoneal”[All Fields] OR “peritonism”[All 
Fields] OR “peritonitis”[MeSH Terms] OR “peritonitis”[All 
Fields]))  OR (“pneumonia”[MeSH Terms] OR 
“pneumonia”[All Fields] OR “pneumoniae”[All Fields] OR 
“pneumonias”[All Fields] OR “pneumoniae s”[All Fields]) 
OR (“sepsis”[MeSH Terms] OR “sepsis”[All Fields]) 
OR (“sepsis”[MeSH Terms] OR “sepsis”[All Fields] OR 
“septicaemias”[All Fields] OR “septicemias”[All Fields] 
OR “septicaemia”[All Fields] OR “septicemia”[All Fields]) 
OR (“bacteraemia”[All Fields] OR “bacteremia”[MeSH 
Terms] OR “bacteremia”[All Fields] OR “bacteraemias”[All 
F i e l d s ]  O R  “ b a c t e r e m i a s ” [ A l l  F i e l d s ] )  O R 
(“meningeal”[All Fields] OR “meninges”[MeSH Terms] 
OR “meninges”[All Fields] OR “meninge”[All Fields] OR 
“meningism”[MeSH Terms] OR “meningism”[All Fields] 
OR “meningisms”[All Fields] OR “meningitis”[MeSH 
Terms] OR “meningitis”[All Fields] OR “meningitides”[All 
Fields]) OR (“abscess”[MeSH Terms] OR “abscess”[All 
Fields] OR “abscesses”[All Fields] OR “abscessation”[All 
Fields] OR “abscessed”[All Fields] OR “abscessing”[All 
Fields]) OR ((“central venous catheters”[MeSH Terms] 
OR (“central”[All Fields] AND “venous”[All Fields] AND 
“catheters”[All Fields]) OR “central venous catheters”[All 
Fields] OR (“central”[All Fields] AND “venous”[All 
Fields] AND “catheter”[All Fields]) OR “central venous 
catheter”[All Fields]) AND (“family”[MeSH Terms] 
OR “family”[All Fields] OR “relation”[All Fields] OR 
“relatability”[All Fields] OR “relatable”[All Fields] 
OR “related”[All Fields] OR “relates”[All Fields] OR 
“relating”[All Fields] OR “relational”[All Fields] OR 
“relations”[All Fields]) AND (“infect”[All Fields] OR 
“infectability”[All Fields] OR “infectable”[All Fields] 
OR “infectant”[All Fields] OR “infectants”[All Fields] 
OR “infected”[All Fields] OR “infecteds”[All Fields] OR 
“infectibility”[All Fields] OR “infectible”[All Fields] OR 
“infecting”[All Fields] OR “infection s”[All Fields] OR 
“infections”[MeSH Terms] OR “infections”[All Fields] 
OR “infection”[All Fields] OR “infective”[All Fields] 
OR “infectiveness”[All Fields] OR “infectives”[All 
Fields] OR “infectivities”[All Fields] OR “infects”[All 
Fields] OR “pathogenicity”[MeSH Subheading] OR 
“pathogenicity”[All Fields] OR “infectivity”[All Fields])) 
OR (“catheter related infections”[MeSH Terms] OR 
(“catheter related”[All Fields] AND “infections”[All 
Fields]) OR “catheter related infections”[All Fields] OR 
(“catheter”[All Fields] AND “related”[All Fields] AND 
“infection”[All Fields]) OR “catheter related infection”[All 
Fields])).
All the selected articles were firstly evaluated on the 
basis of titles and abstracts. If it was not possible to make 
a decision in this way, the full-text article was analyzed. If 
the authors did not agree on the inclusion of an individual 
article in the systematic review, the senior researcher made 
the final decision.
From each article that met the inclusion criteria, the 
following data were extracted and inserted into an Excel 
file: (1) Publication ID, (2) Report ID, (3) Review author 
initials, (4) Citation and contact details, (5) Eligibility for 
review, (6) Study design, (7) Total study duration, (8) Risk 
of bias, (9) Total number of patients, (10) Age of patients, 
(11) Gender of patients, (12) Country, (13)  Presence of 
hypertension, (14) Presence of diabetes, (15) Presence of 
a malignancy, (16) Postoperative infections, (17) Infections 
on embedded artificial materials, (18) Site of C. striatum 
isolation (body fluid or tissue), (19)  Sampling method, 
(20)  Method of C.  striatum identification (biochemical 
methods and/or MALDI TOF and/or 16S RNA sequencing), 
(21) Maximal level of serum C-reactive protein (CRP) during 
the infection, (22) Maximal level of serum procalcitonin 
(PCT) during the infection, (23) Maximal white cells 
count (WBC) during the infection, (24)  Diagnosis, 
(25) Morphological diagnoses that confirmed the invasive 
infection (NMR, ultrasound, etc.), (26) Presence of clinical 
signs of systemic infection (body temperature, heart rate, 
blood pressure, respiratory rate etc.), (27) Changes in 
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biochemical parameters suggestive of organ (or tissue) 
infection, (28) Antibiotic regimen used, (29) Duration of the 
antibiotic therapy, (30) Outcomes of the antibiotic treatment 
(cure rate and mortality), (31) Adverse events rate and type, 
(32) Sensitivity to antibiotics, (33) Resistance to antibiotics.
Postoperative infection was considered to be any 
infection that occurred after a surgical intervention, with 
the development of symptoms during the postoperative 
recovery (while the patient was still hospitalized). Patients 
who developed symptoms after discharge from the hospital, 
after a certain period of time, were not considered as 
postoperative infections.
Infections on artificial materials (grafts) were considered 
if C.  striatum was detected from the sample taken from 
the graft itself (central venous catheter, artificial valve, 
etc.) or from an adjacent tissue. The extraction of data was 
performed independently by each investigator.
For each study included (according to their design), 
all authors assessed four types of bias (i.e. selection, 
information, attrition and outcome reporting bias) 
separately and independently, and in case of disagreement, 
the final decision was made by the senior investigator (SJ). 
In addition, the uniformity of the tabular presentation of the 
included studies according to their distribution in different 
regions of the world in which they were conducted, was 
assessed. 
The continuous variables (categorical) measured in this 
analysis were: total study duration, total number of patients, 
age of patients, maximal level of CRP, PCT and WBC during 
the infection and duration of antibiotic therapy, while the 
gender of patients, presence of hypertension, diabetes or 
malignancy, postoperative infection, infections on embedded 
artificial materials, site of C.  striatum isolation, sampling 
method, method of C. striatum identification, morphological 
diagnoses that confirmed the invasive infections, presence of 
clinical signs of systemic infection, changes in laboratory 
parameters, antibiotic regimen used, outcomes of antibiotic 
treatment (cure rate and mortality), adverse events rate and 
type, sensitivity and resistance to antibiotics.
Each individual patient from the articles included in this 
review was considered as the unit of analysis.
The authors tried to reduce the percentage of missing 
data by searching them getting in contact with the 
researchers who conducted the original researches or 
by searching for data within the Results category in the 
ClinicalTrial.gov database. Within the Discussion section, 
the impact of missing data on the final results and possible 
conclusions was discussed. The heterogeneity evaluation 
could not be applied to this type of systematic review.
Basic methods of descriptive statistics (median and 
interquartile range for continuous variables and numbers 
and percentages for the categorical variables) were used to 
analyze and present the data.
RESULTS
Characteristics of included studies and patients
The literature search results are summarized in 
Figure 1. The final analysis covered a total of 42 studies 
(35 case reports1,2,12-44 and 7 case series5,9,45-49) reporting 
85 individual cases that met the inclusion criteria and did 
not present exclusion criteria. The median age of the subject 
with the reported C.  striatum invasive infection was 65 
(IQR 51, 72), with the oldest being 88 years old, while the 
youngest was 13 years old. About two/thirds of the cases 
were males (57/67.1%), 27 cases (31.8%) were females, 
while in 1 case (1.2%) the gender of the patient was not 
reported. The presence of hypertension was reported in 
15 patients (17.6%), 14 patients (16.5%) had diabetes, while 
various types of cancers were reported in 13 cases (15.3%). 
C.  striatum caused postoperative infections (infections 
after invasive diagnostic and therapeutic procedures) in 
24 patients (28.2%). On the other hand, the causal role of 
C. striatum for infections of previously embedded artificial 
implants, such as orthopedic prostheses, artificial valves, 
etc., was reported in 19 patients (22.3%). This systematic 
review article included patients with C. striatum invasive 
infection from European (n=48), Asian (n=17), North 
American (n=16), South American (n=3) and African 
continents (n=1). Most of the cases were reported from 
Spain (17/20%), followed by USA (15/17.6%), India 
(13/15.3%), France (12/14.1%), Italy (10/11.8%) and 
England (4/4.7%). Korea, Japan and Brazil reported two 
patients each with invasive infections caused by C. striatum 
(2/2.3%), while Morocco, Colombia, Greece, Northern 
Ireland, Canada, Turkey, Belgium and Netherland reported 
only one case each (1.2%). The geographical distribution of 
included cases is presented in Figure 2. All patients involved 
were managed exclusively in hospitals. The longest follow-
up last about 14 months24. In five of six case series included, 
the attrition bias was evaluated as low, while in one study5, 
we estimated it to be medium, because the authors reported 
two lost-to-follow-up patients. Overview of the individual 
cases, as well as an assessment of the risk of bias in each 
study included are shown in Supplementary Table S1.
Site and method of isolation of Corynebacterium 
striatum
The presence of C. striatum was the most commonly 
confirmed in blood samples (24/28.2%), followed by 
Rev Inst Med Trop São Paulo. 2021;63:e49
Antimicrobial treatment of Corynebacterium striatum invasive infections
Page 5 of 15
intra- and postoperative samples from bone and joint 
infections (13/15.3%), sputum (12/14.1%), bronchial 
aspirate (9/10.6%), ulcer aspirate (5/5.9%), central venous 
catheter (4/4.7%), wound aspirate (4/4.7%), synovial fluid 
aspirate (3/3.5%) nasal swab (2/2.3%), tracheal aspirate 
(2/2.3%), and broncho-alveolar lavage fluid (2/2.3%). 
C.  striatum was isolated in one patient each from pus, 
continuous ambulatory peritoneal dialysis fluid, pleural 
fluid, cerebrospinal fluid, wound swab, throat swab, urine, 
as well as from samples obtained from uterus, placenta, 
IV catheter, lung biopsy, excised necrotic breast tissues, 
skin lesion biopsy, drainage of abscess and chest drainage. 
C.  striatum as a cause of infection was most often 
identified exclusively by biochemical methods (37/43.5%), 
while additional confirmation using 16S rRNA gene 
sequencing was carried out in 7 (8.2%) cases. On the other 
hand, mass spectrometry (in the vast majority of cases 
through the MALDI-TOF system) as a single method was 
used to identify C.  striatum in 17 patients (20%), while 
the causative agent was identified by a combination of 
biochemical methods and MALDI-TOF in 12 patients 
(14.1%). 16S rRNA sequencing was the only method for 
identification of C. striatum in 9 patients (10.6%), while 
in 2 cases (2.3%) corynebacteria were identified by a 
combination of MALDI-TOF and 16S rRNA sequencing. 
Finally, in one patient (1.2%) an invasive infection caused 
by C.  striatum was confirmed by a combination of all 
three methods (biochemical+MALDI-TOF+16S rRNA 
sequencing).
Susceptibility of C. striatum to antibiotics
Antimicrobial susceptibility testing of C. striatum was 
performed in 64 patients (75.3%), and the summarized 
susceptibility pattern of these isolates is depicted in Figure 3. 
When more than two isolates were reported to perform the 
susceptibility testing for specific antibiotics, all isolates 
were found to be susceptible to vancomycin (50/78.1%), 
linezolid (30/46.9%), teicoplanin (16/25%), piperacillin-
tazobactam (8/12.5%), amoxicillin-clavulanate (3/4.7%) 
and cefuroxime (2/3.1%). On the other hand, all the isolates 
Figure 1 - The study selection flowchart. 
Figure 2 - Geographical distribution of Corynebacterium striatum studies. Countries in which C. striatum was isolated are shaded 
with grey color. 
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tested to levofloxacin (15/23.4%), cefalotin (8/12.5%), 
cefoperazone (8/12.5%), aztreonam (8/12.5%), doxycycline 
(8/12.5%), etC. were resistant. Isolates of C. striatum have 
also shown a high degree of resistance to penicillin (32 vs. 
6 susC. isol.), cefazoline (8 vs. 1 susC. isol.), ceftriaxone 
(13 vs. 3 susC. isol), ceftazidime (10 vs. 1 susC. isolates), 
gentamycin (16 vs. 12 susC. isol.), erythromycin (19 vs. 13 
susC. isol.), tetracycline (18 vs. 3 susC. isol., cotrimoxazole 
(16 vs. 4 susC. isol.), ciprofloxacin (20 vs. 5 susC. isol) and 
particularly to clindamycin (34 vs. 1 susC. isol).
Antibiotic treatment of C. striatum infections
Antibiotics used for treatment of invasive infections 
caused by C. striatum were reported in 83 patients (97.6%). 
Treatment of C. striatum invasive infections in a slightly 
higher number of patients (44/53%) was composed of a 
monotherapeutic antibiotic approach, while a combination 
of two or more antibiotics was used for the treatment of 
39 patients (47%). Vancomycin was the most commonly 
used antibiotic (35/42.2%), followed by piperacillin-
tazobactam (20/24.1%), rifampicin (11/13.2%) and 
amoxicillin (11/13.2%) (Figure 4). Adverse effects of the 
applied antibiotics were reported only for patients with 
endocarditis, in whom a cutaneous rash occurred during 
the administration of ampicillin and gentamicin, leading 
to the replacement of this combination of antibiotics by 
vancomycin.
Treatment outcomes
More than half of the patients (62.3%) experienced a 
complete recovery after the antibiotic treatment, while in 
12 patients (14.1%) a relevant clinical improvement was 
Figure 3 - Susceptibility of C. striatum to antibiotics.
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reported after the administration of the antibiotic therapy. 
Death was reported in 15 patients (17.6%), while failure of 
the antibiotic therapy resulted in recurrence, superinfection 
and limb amputation, reported in three patients (3.5%) with 
orthopedic infections. Finally, the treatment outcome was 
not reported in two patients (2.3%). 
DISCUSSION
This systematic review confirmed the clinical relevance 
of C.  striatum as a cause of various serious infections 
both in immunocompromised and immune competent 
inpatients. C.  striatum was isolated from different types 
of biological and artificial samples and more frequently 
identified by specific biochemical tests in slightly more 
than 43% of the total number of patients. This bacterial 
species was also recovered from different infection sites, 
depending on the infected tissue. More than one isolate of 
C. striatum exhibited 100% susceptibility to vancomycin, 
linezolid, teicoplanin, piperacillin-tazobactam, amoxicillin-
clavulanate and cefuroxime, while strains of this bacterium 
showed a high degree of resistance to fluoroquinolones, the 
vast majority of β-lactams, aminoglycosides, macrolides, 
lincosamides and cotrimoxazole. Despite the use of 
antibiotics, fatal outcome was reported in almost 20% of 
the patients included in this study. 
As a normal resident of the human skin and mucous 
membranes C. striatum is rarely a pathogenic microorganism. 
However, it seems that C. striatum has a particularly large 
pathogenic potential among non-diphtheritic bacteria from 
the genus Corynebacterium4. Microbiological in vitro 
studies have shown that the ability to form a biofilm on 
different abiotic surfaces stands out as the most significant 
virulence factor possessed by this bacterium50,51. C. striatum 
forms colonies equally efficiently on both, hydrophobic 
and hydrophilic surfaces, including polystyrene ureters. It 
could be expected that the C. striatum potential for biofilm 
formation is even higher in vivo due to the stimulatory 
effect of fibrinogen52. Biofilm makes bacteria more resistant 
to the action of immune system cells and antibiotics, 
which explains the growing number of bloodstream and 
catheter-related infections caused by C.  striatum50,51. 
Microbial biofilms play a key role in the pathogenesis of 
endocarditis53, which may explain the fact that this review 
includes as many as 10 reports of endocarditis caused by 
C. striatum12,20,21,24-27,29,42,43. We also analyzed more than 
10 cases with C.  striatum prosthetitis, catheter-related 
infections and similar infections on embedded artificial 
devices and materials2,5,9,19,22,30, which are most likely 
a consequence of the aforementioned virulence factor 
available to this bacterium.
When it comes to the diagnostic method for identifying 
C. striatum, at least several examples of misidentification 
of this bacterium using biochemical methods have been 
reported in the literature. A particularly interesting case 
was reported in the intensive care unit of a clinic in 
Messina, Italy45. At the beginning of 2006, in eight patients 
with symptoms of severe infection, the causative agent 
was initially misidentified as Kocuria kristinae using 
the conventional Vitek 2 system (bioMérieux, Marcy 
L’Étoile, Lyon, France). Different types of biological 
samples (7 bronchial aspirates from 5 patients, 5 sets of 
blood cultures from two patients and one sample from a 
central venous catheter) were tested and the probability of 
identification was extremely high, of 99.9%. However, 16S 
rRNA sequencing was subsequently performed and all the 
13 isolates were identified as C. striatum. The results of 
several studies54-56 indicate that gene sequencing methods 
are the most reliable for identifying C. striatum and should 
be the gold standard for the identification of this bacterium. 
MALDI-TOF is a slightly less accurate method than 16S 
rRNA sequencing, but due to its cost-efficiency, simplicity 
and sufficient reliability, it can be used as an alternative 
Figure 4 - Antibiotics used for the treatment of C.  striatum 
infections.
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method for the identification of C. striatum54,55. Although 
cases of misdiagnosis of C. striatum using the VITEK 2 
system (bioMerieux) can be found in clinical practice45, 
it could be considered that this method of identification of 
C. striatum is reliable after the inclusion of this pathogen 
in the database of the VITEK system (VITEK®2 ANC ID 
card)57, especially in laboratories which do not dispose 
of equipments for the 16S rRNA sequencing or the 
MALDI-TOF. 
In recent years, C.  striatum has been classified as 
multidrug-resistant, which is confirmed by the results 
of this systematic review article, due to a high degree of 
resistance showed to fluoroquinolones, the vast majority 
of β-lactams, aminoglycosides, macrolides, lincosamides 
and cotrimoxazole. Molecular mechanisms of resistance 
of C. striatum to these classes of antibiotics are already 
known. Resistance of C.  striatum to fluoroquinolones is 
the most likely result of mutations at codons 87 and 91 of 
the QRDR gyrA gene58, while resistance of this bacterium 
to β-lactams is most likely a consequence of synthesis of 
β-lactamase3. The presence of multiresistance plasmid 
pTP10 explains the resistance that this bacterium shows 
to macrolides, tetracyclines and clindamycin59. However, 
despite the problem of resistance that C. striatum showed 
to a large number of antibiotics, our review confirmed a 
good in vitro susceptibility of this bacterium primarily 
to vancomycin, linezolid, teicoplanin and piperacillin-
tazobactam, without any case of resistance. High resistance 
of C. striatum strains towards macrolides, lincosamides, 
fluoroquinolones, β-lactams and rifampicin on the one 
hand, respectively 100% susceptibility to vancomycin, 
daptomycin and linezolid, on the other hand, was also 
shown by Alibi et al.3.
 This systematic review has several limitations. Firstly, 
a relatively small number of reported cases with invasive 
infections caused by C. striatum was analyzed. Secondly, 
16S rRNA gene sequencing as the most accurate method 
for confirming C. striatum in different isolates was used 
in a minority of studies included in our review, implying 
a controversial reliability in terms of correct identification 
of this bacterium. Finally, in several analyzed reports, 
relevant information on the susceptibility of C.  striatum 
to antibiotics, the applied antibiotic therapy, as well as on 
all the outcomes of treatment of the infections, were either 
missing or incompletely presented.
CONCLUSION
In conclusion, C. striatum could play a pathogenic role 
in causing serious invasive infections of various tissues 
accompanied by a significant mortality rate, predominantly 
in elderly patients and in those with significant level of 
immunosuppression, but also in immunocompetent hosts 
The gold standard for identifying C. striatum are the gene 
sequencing techniques, but the MALDI-TOF and Vitek 2 
system can also be used with significant reliability, especially 
when there is a need for a rapid identification of the causative 
agent. Vancomycin, a broad-spectrum glycopeptide should 
be used as the antibiotic of choice, as monotherapy or in 
combination with piperacillin-tazobactam, depending on the 
type and severity of the infection. Alternatively, linezolid, 
teicoplanin or daptomycin may be used in severe infections, 
while amoxicillin-clavulanate may be used to treat only 
mild infections caused by C. striatum, if their potential use 
matches the results of the in vitro activity findings. Duration 
of antibiotic therapy should be adjusted according to the 
severity and anatomical site of the infection. During the 
administration of vancomycin, regular monitoring of renal 
function is necessary, especially in elderly patients. On the 
other hand, the use of linezolid for the treatment C. striatum 
infections requiring several months of treatment should 
be avoided, because the prolonged use of this antibiotic is 
accompanied by a higher risk of serious side effects.
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